Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0V4FP
|
|||
| Former ID |
DIB001041
|
|||
| Drug Name |
OX-30
|
|||
| Synonyms |
Opioid (oral controlled-release, pain), Orexo
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Pain [ICD-11: MG30-MG3Z] | Terminated | [1] | |
| Company |
Orexo AB
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Dehalobacteriaceae
Show/Hide Hierarchy
|
[2], [3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Constipation | |||
| Description | The abundance of Dehalobacteriaceae was decreased by Opioid. | |||
|
Studied Microbe: Eubacteriaceae
Show/Hide Hierarchy
|
[2], [3] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Constipation | |||
| Description | The abundance of Eubacteriaceae was increased by Opioid. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Lactobacillales | ||||
|
Studied Microbe: Lactobacillaceae
Show/Hide Hierarchy
|
[2], [3] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Constipation | |||
| Description | The abundance of Lactobacillaceae was increased by Opioid. | |||
|
Studied Microbe: Streptococcaceae
Show/Hide Hierarchy
|
[2], [3] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Constipation | |||
| Description | The abundance of Streptococcaceae was increased by Opioid. | |||
|
Studied Microbe: Streptococcus salivarius
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Inflammatory bowel disease | |||
| Description | The abundance of Streptococcus salivarius was increased by Opiate alkaloids. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Micrococcales | ||||
|
Studied Microbe: Micrococcaceae
Show/Hide Hierarchy
|
[2], [3] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Constipation | |||
| Description | The abundance of Micrococcaceae was increased by Opioid. | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Leukocyte common antigen (PTPRC) | Target Info | . | [5] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| T cell receptor signaling pathway | ||||
| Fc gamma R-mediated phagocytosis | ||||
| Primary immunodeficiency | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| Panther Pathway | B cell activation | |||
| JAK/STAT signaling pathway | ||||
| T cell activation | ||||
| Pathway Interaction Database | BCR signaling pathway | |||
| TCR signaling in naï | ||||
| TCR signaling in naï | ||||
| CXCR4-mediated signaling events | ||||
| Reactome | Phosphorylation of CD3 and TCR zeta chains | |||
| Other semaphorin interactions | ||||
| WikiPathways | Interferon type I signaling pathways | |||
| EPO Receptor Signaling | ||||
| B Cell Receptor Signaling Pathway | ||||
| TCR signaling | ||||
| Semaphorin interactions | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027164) | |||
| REF 2 | Interaction between drugs and the gut microbiome. Gut. 2020 Aug;69(8):1510-1519. | |||
| REF 3 | Gut microbiota associations with common diseases and prescription medications in a population-based cohort. Nat Commun. 2018 Jul 9;9(1):2655. | |||
| REF 4 | Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nat Commun. 2020 Jan 17;11(1):362. | |||
| REF 5 | CD45 / PTPRC Antibody, Biotin conjugate (OX-30). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.